Claudio Mussolino,Tafadzwa Mlambo,Toni Cathomen
Claudio Mussolino
Targeted gene editing with designer nucleases has become increasingly popular. The most commonly used designer nuclease platforms are engineered meganucleases, zinc-finger nucleases, transcription activator-like effector nucleases and the c...
Oksana Sulaieva,John L Wallace
Oksana Sulaieva
Among the most commonly used drugs, nonsteroidal anti-inflammatory drugs (NSAIDs) remain problematic because of their propensity to cause serious adverse events, principally affecting the gastrointestinal tract. In recent years, the discove...
Hildegard Büning,Anke Huber,Liang Zhang et al.
Hildegard Büning et al.
Adeno-associated viral (AAV) vectors are the most widely used delivery system for in vivo gene therapy. Vectors developed from natural AAV isolates achieved clinical benefit for a number of patients suffering from monogenetic disorders. How...
Felix Junyent,Eric J Kremer
Felix Junyent
Canine adenovirus type 2 (CAV-2) vectors are powerful tools for fundamental and applied neurobiology due to their negligible immunogenicity, preferential transduction of neurons, widespread distribution via axonal transport, and duration of...
Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells [0.03%]
用于基因治疗靶向细胞基因转移的慢病毒载体表面工程化改造
Camille Lévy,Els Verhoeyen,François-Loïc Cosset
Camille Lévy
Since they allow gene integration into their host genome, lentiviral vectors (LVs) have strong therapeutic potentials, as emphasized by recent clinical trials. The surface-display of the pantropic vesicular stomatitis virus G glycoprotein (...
Leszek Lisowski,Szun Szun Tay,Ian Edward Alexander
Leszek Lisowski
Gene transfer vectors based on adeno-associated virus (AAV) are showing exciting therapeutic promise in early phase clinical trials. The ability to cross-package the prototypic AAV2 vector genome into different capsids is a powerful way of ...
An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies [0.03%]
针对RNA的反义寡核苷酸药物临床应用概述
Graham McClorey,Matthew J Wood
Graham McClorey
Despite the discovery more than two decades ago that antisense oligonucleotides (ASOs) could be used to modulate protein expression, there have been only two antisense drugs approved for clinical use till date. Despite this low success rate...
New antibiotics against gram-positives: present and future indications [0.03%]
新的抗革兰氏阳性菌抗生素：目前及未来的适应症
Laura Morata,Josep Mensa,Alex Soriano
Laura Morata
Gram-positive cocci are the most frequent aetiology of community and nosocomially bacterial acquired infections. The prevalence of multidrug-resistant gram-positive bacteria is increasing and is associated with high morbidity and mortality....
Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice [0.03%]
移植患者中唑类抗真菌药与选择免疫抑制剂相互作用的临床实践管理策略优化探究
Vincent J C Lempers,Lisa C Martial,Michiel F Schreuder et al.
Vincent J C Lempers et al.
The management of drug-drug interactions (DDIs) between azole antifungals (fluconazole, itraconazole, posaconazole and voriconazole) and immunosuppressants (cyclosporine, tacrolimus, everolimus and sirolimus) in transplant patients remains ...